Condition: Indolent B-Cell Non-Hodgkin Lymphoma · Sponsor: Koo Foundation Sun Yat-Sen Cancer Center
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
This description comes directly from the study's public registry record.
Yu Yi Huang, MD · +886 28970011 · yuyi@kfsyscc.org
Cheng Ling Yang, B.Rad. · +886 28970011 · androgyny@kfsyscc.org
Always discuss trial participation with your own doctor first.
| Koo Foundation Sun Yat-Sen Cancer Center | Taipei, Beitou, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06461182